伊立替康联合替吉奥治疗晚期食管癌的疗效评价  

Efficacy of Irinotecan Combined with S-1 in the Treatment of Advanced Esophageal Carcinoma

作　　者：李冰洁[1] 樊青霞[1] 

机构地区：[1]郑州大学第一附属医院肿瘤科,河南郑州450052

出　　处：《肿瘤基础与临床》2016年第6期479-482,共4页journal of basic and clinical oncology

摘　　要：目的观察伊立替康联合替吉奥治疗晚期食管癌的疗效及不良反应。方法经组织学证实的43例晚期食管癌患者接受化疗:伊立替康80 mg·m^(-2),持续静脉滴注90~120 min,d1,8;替吉奥80 mg·m^(-2),bid,d_(1-14),21 d为1周期,每2周期化疗后进行疗效评价。结果 43例患者共完成169周期化疗,在可评价疗效的41例患者中,CR 1例,PR 10例,SD 14例,PD 16例,有效率为26.8%(11/41),疾病控制率为61.0%(25/41)。中位疾病进展时间为5.6个月,中位总生存时间为9.8个月。化疗主要不良反应为胃肠道反应和血液学毒性。结论伊立替康联合替吉奥治疗晚期食管癌疗效显著、不良反应轻、患者依从性好,可作为晚期食管癌的治疗方案。Objective To investigated the clinical efficacy and toxicities of the combination chemotherapy of S-1 plus irinotecan for esophageal carcinoma. Methods A total of 43 patients with histopathologically confirmed vaneed esophageal carcinoma received the combination chemotherapy of S-1 plus irinotecan. S-1 was administered orally at a dose orS0 mg · m-2 from day 1 to 14,and irinotecan was given intravenously on clay 1 and 8 at a close of 80 mg·m-2. The effect was evaluated at least after 2 cycles. Results The 43 patients completed altogether 169 cycles. In the 41 patients whose effects were evaluable, 1 patient experienced CR, 10 patients PR, 14 patients SD, and 16 patients PD. The overall response rate was 26.8% ,and the disease control rate was 61.0%. The median time to disease progression was 5.6 months, the median overall survival time was 9.8 months. The main toxicities of chemotherapy were gastrointestinal reaction and hematological toxicities. Conclusion The combination chemotherapy of S-1 plus irinotecan is effective and safe for advanced esophageal carcinoma.

关 键 词：伊立替康 替吉奥 晚期食管癌 

分 类 号：R735.1[医药卫生—肿瘤] R730.53[医药卫生—临床医学]